AbbVie Inc.ABBV

$216.49-4.74 (-2.14%)

NYSEHealthcareDividend King24:00 UTC

Company snapshot

Market Cap

$384B

Mega-cap

+285%

2016 — today

10-Year Price

+253%

2016 — today

52-Week Range

$182.31$244.38

Current $216.49· 55%

AbbVie discovers, develops, and commercializes advanced biopharmaceuticals. Its portfolio spans: Immunology (HUMIRA, SKYRIZI, RINVOQ); Oncology (IMBRUVICA, VENCLEXTA); Virology (MAVYRET); Gastroenterology/Endocrinology (CREON, Synthroid, Linzess); Women’s Health/Urology (Lupron, ORILISSA); Neurology (Duopa, Ubrelvy, Botox); and Ophthalmology (Lumigan, Alphagan, Restasis). Spun off in 2012 and based in North Chicago, the firm maintains extensive research collaborations, including partnerships with Dragonfly Therapeutics.